Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 11INDUSTRY 5FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

enzalutamide 4pembrolizumab 3Docetaxel 3apalutamide 2Testosterone 2Prednisone 2Cholecalciferol 2Celecoxib 2Androgen Antagonists 2Abiraterone Acetate 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2relugolix 1olaparib 1nilutamide 1histrelin 1gallium 68 PSMA-11 1capivasertib 1bicalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abiraterone 1Yoga 1Triptorelin Pamoate 1Tablets 1Simvastatin 1Sildenafil Citrate 1Pluvicto 1Perioperative Care 1Pentoxifylline 1Methylprednisolone 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Prostatic Neoplasms × Drug Therapy × Clear all
NCT00108290 2008-04-04

Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer

VA Office of Research and Development

Phase 2 Completed
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡